Chemicals & Small Molecules

Carbidopa is a decarboxylase inhibitor used in conjunction with levodopa in patients with Parkinson's disease. Carbidopa inhibits the peripheral metabolism of levodopa, which allows a greater proportion of the levodopa to cross the blood - brain barrier for central nervous system effects,

Levodopa is a dopamine precursor that is being studied as a potential treatment for the symptoms of Parkinson's disease. Levodopa crosses the blood brain barrier where it is converted to dopamine by DOPA decarboxylase.

NAD+ covalently labeled with biotin (6-biotin-17-nicotinamide-adenine-dinucleotide). Can be used as a substrate by poly(ADP-ribosyl) polymerase (PARP) enzymes for generating biotin-labeled ADP-ribose monomers in PARylation reactions.

Streptavidin-HRP is useful in select BPS Bioscience assay kits.

Ruxolitinib, also known as INCB18424, is a potent and selective Janus kinase JAK1 and JAK2 inhibitor, with IC50s of 5.9 nM and 5.7 nM, respectively. It inhibited IL-6 and IL-23 effects at concentrations less than 50 nM. Ruxolitinib was effective in the rat adjuvant arthritis model and multiple murine models of arthritis.

Ruxolitinib, also known as INCB18424, is a potent and selective Janus kinase JAK1 and JAK2 inhibitor, with IC50s of 5.9 nM and 5.7 nM, respectively. It inhibited IL-6 and IL-23 effects at concentrations less than 50 nM. Ruxolitinib was effective in the rat adjuvant arthritis model and multiple murine models of arthritis.

NLG919 is an orally available potent inhibitor of the indoleamine-2,3- dioxygenase (IDO1) pathway, a crucial pathway involved in allergic inflammation that mediates immunosuppressive effects through metabolization of tryptophan to kynurenine. NLG919 affects differentiation and proliferation of T cells by inducing downstream signaling via GCN2, mTOR and AHR, with values of Ki = 7 nM and EC50 = 75 nM. NLG919 is being investigated for the treatment of immunosuppression associated with cancer.

NLG919 is an orally available potent inhibitor of the indoleamine-2,3- dioxygenase (IDO) pathway, a crucial pathway involved in allergic inflammation that mediates immunosuppressive effects through metabolization of tryptophan to kynurenine. NLG919 affects differentiation and proliferation of T cells by inducing downstream signaling via GCN2, mTOR and AHR, with values of Ki = 7 nM and EC50 = 75 nM. NLG919 is being investigated for the treatment of immunosuppression associated with cancer.

INCB024360 analog is an orally available hydroxyamidine and inhibitor of indoleamine 2,3- dioxygenase (IDO1), with an IC_50?? of 10 nM. It shows little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). INCB024360 analog displays potential immunomodulating and antineoplastic activities.